Zeleciment Rostudirsen
Neuromuscular Disease
Dyne TherapeuticsUNKNOWNPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Neuromuscular Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Apitegromab Scholar Rock, Inc. | Phase 3 | BB |
Ataluren PTC Therapeutics | Phase 3 | B |
Deramiocel Capricor Inc. | Phase 3 | B |
Taldefgrobep Alfa Biohaven Pharmaceuticals, Inc. | Phase 3 | B |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | B |
View all 16 →
Same molecule, other indications
Zeleciment Rostudirsen is also rated in:
neuromuscular disease caused by qualitative or quantitative defects of dystrophinActive
B
Indicative · Phase 3
60 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →